Close

Strongbridge Biopharma (SBBP) Announces Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV (levoketoconazole) at ENDO 2021 Meetings

Go back to Strongbridge Biopharma (SBBP) Announces Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV (levoketoconazole) at ENDO 2021 Meetings
(NASDAQ: SBBP) Delayed: 2.00 --0 (-0%)
Previous Close $2.00    52 Week High $7.99 
Open $0.11    52 Week Low $3.30 
Day High $2.00    P/E N/A 
Day Low $2.00    EPS $0.00 
Volume 21,283,258